DaVita Inc. provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver.
In 2023, 67% of the company's revenues came from Medicare and other government-based health insurance programs. In 2023, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 33% of revenues in 2023, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 341st on the Fortune 500.
The name "DaVita" was derived from the Italian language phrase "Dare Vita", which means "to give life".